Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cardio-Oncology Multidisciplinary Patient ASsistance Solution

Project description

Protecting the heart during and after cancer treatment

Cancer therapies can damage the heart, a complication known as cardiotoxicity. The management of this risk presents significant challenges due to the absence of reliable early warning markers. Consequently, clinicians are often forced to reduce or discontinue cancer treatment. The EU-funded COMPASS project addresses this issue by implementing a comprehensive, patient-centred cardio-oncology programme. The consortium aims to discover novel biomarkers, develop AI-supported imaging tools, and integrate wearable technologies for early detection and personalised management of cardiovascular complications. COMPASS will integrate clinical research, digital innovation, and patient engagement to improve outcomes for cancer patients without compromising the effectiveness of their treatment.

Objective

The rise in cardiovascular disease among cancer patients and survivors, due to treatment side effects, poses a significant challenge to patient outcomes and healthcare systems. Managing cardiotoxicity is difficult due to its delayed onset and lack of reliable biomarkers, often requiring dose reduction or discontinuation of cancer treatment, which may compromise its effectiveness.

The COMPASS project aims to optimize cardiovascular health for cancer patients and survivors through a comprehensive, patient-centered clinical pathway over five years. It will advance cardio-oncology research by creating an international network and developing tools for better disease prediction, prevention, diagnosis, and management. The project focuses on integrating cardio-oncology care pathways, optimizing diagnostic biomarkers, and utilizing AI-supported imaging and wearable technologies for early detection and personalized treatment, while promoting sustainable healthcare delivery and reducing environmental impact.

COMPASS methodology includes three pillars: (i) Discovery of Novel Biomarkers and Parameters, (ii) AI Prediction Models and Clinical Decision Support System, and (iii) Improving Care Delivery and Patient Engagement. Activities across the program include Health Economics, Communication, Dissemination, Exploitation and Sustainability, and Ethics and Regulatory Aspects. This public private partnership of 51 academic and industrial partners will collaborate to translate scientific advancements into clinical applications, apply novel AI approaches, ensuring solutions are effective, meet patient needs, and align with European health policies and regulations. Key stakeholders include clinicians, nurses, patients, payers, regulators, and industry actors. COMPASS aims to advance cardio-oncology research, reduce healthcare costs, and improve patient well-being through innovative tools, collaborative networks, and policy support. Ultimately, it aims to improve patient outcomes for both cancer and heart health.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2025-09-single-stage

See all projects funded under this call

Coordinator

KING'S COLLEGE LONDON
Net EU contribution
€ 1 538 740,00
Address
STRAND
WC2R 2LS London
United Kingdom
Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 538 740,00

Participants (61)

Partners (2)